Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Bayer says Monsanto...

    Bayer says Monsanto deal on track, eyes record 2017

    Written by supriya kashyap kashyap Published On 2017-02-23T10:27:34+05:30  |  Updated On 23 Feb 2017 10:27 AM IST
    Bayer says Monsanto deal on track, eyes record 2017

    Frankfurt : German pharmaceuticals and chemicals giant Bayer reported record sales and profits for 2016 and said it expected further growth in 2017, as its goal to seal a mammoth takeover of US seed maker Monsanto remains on track.


    "We again posted a record operating performance and are making good progress with the agreed acquisition of Monsanto as well," chief executive Werner Baumann said in a statement.


    The Aspirin-maker said net profit grew by 10.2 percent to 4.5 billion euros ($4.7 billion) last year, slightly below the 4.7 billion euros analysts surveyed by Factset had expected.


    Group sales increased by 1.5 percent to 46.8 billion euros, in line with expectations, while underlying or operating profit before special items was up 10.2 percent at 11.3 billion euros.


    Growth was mainly powered by Bayer's prescription medicine division, led by a 30-percent jump in sales for its blockbuster drug Xarelto, an anti-coagulant.


    The over-the-counter medicines unit, which includes household brands such as Alka-Seltzer and Rennie antacids, saw earnings fall.


    The firm's closely watched agrochemicals division disappointed in 2016, hit by what Bayer said was a weak market environment "particularly in Latin America" and falling demand for insecticides globally.


    Bayer's agriculture activities are in the spotlight as it seeks a $66-billion takeover of US seed and pesticide supplier Monsanto, in what would be the largest ever acquisition by a German firm.


    The deal still requires regulatory approval from the European Union and the United States.


    "Bayer and Monsanto are working closely with the authorities. Bayer remains confident of closing the transaction before the end of 2017," the firm said in a statement.


    The proposed tie-up would create an agrochemical behemoth which environmental activists who have called the deal a "marriage made in hell" fear would hold excessive power over farmers and the food chain.


    Looking ahead, Bayer said it expects group sales to grow to more than 49 billion euros in 2017, and a "mid-to-single-digit percentage" increase in underlying profits.


    "We have every reason to be optimistic about the future and started the new business year well," said Baumann.


    Bayer had already announced that it would pay out an increased divided for 2016 of 2.70 euros per share, up from 2.50 euros for 2015.

    AcquisitionAspirinBayereyes record 2017MonsantoWerner BaumannXarelto
    Source : AFP

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok